Table 1 Characteristics of the cohort at baseline in the discovery cohort
From: Preoperative splenic area as a prognostic biomarker of early-stage non-small cell lung cancer
Variable | Total (n = 2532)1 | Splenic area | P value2 | |
|---|---|---|---|---|
Normal (n = 727)1 | Abnormal (n = 1805)1 | |||
Age, years | Â | Â | Â | Â |
Mean (SD) | 58.82 (9.56) | 58.24 (9.33) | 59.05 (9.64) | 0.05 |
Median (IQR) | 59.00 (52.00,66.00) | 57.00 (52.00,65.00) | 59.00 (52.00,66.00) | 0.04 |
Sex, n (%) | Â | Â | Â | <0.001 |
Female | 1158 (45.73) | 383 (52.68) | 775 (42.94) | Â |
Male | 1374 (54.27) | 344 (47.32) | 1030 (57.06) | Â |
Smoking history, n (%) | Â | Â | Â | 0.008 |
Never smoker | 1476 (58.29) | 457 (62.86) | 1019 (56.45) | Â |
Current or former smoker | 1022 (40.36) | 259 (35.63) | 763 (42.27) | Â |
Unknown | 34 (1.34) | 11 (1.51) | 23 (1.27) | Â |
Preoperative CEA, ng/mL | Â | Â | Â | Â |
Mean (SD) | 13.82 (156.60) | 12.14 (85.85) | 14.50 (177.35) | 0.67 |
Median (IQR) | 3.30 (2.05,5.79) | 3.11 (2.04,5.70) | 3.34 (2.05,5.80) | 0.23 |
Tumor location, n (%) | Â | Â | Â | 0.61 |
Upper lobe | 1277 (50.43) | 356 (48.97) | 921 (51.02) | Â |
Non–upper lobe | 1248 (49.29) | 369 (50.76) | 879 (48.70) |  |
Unknown | 7 (0.28) | 2 (0.28) | 5 (0.28) | Â |
Surgical approach, n (%) | Â | Â | Â | 0.63 |
Thoracoscope | 1591 (62.84) | 457 (62.86) | 1134 (62.83) | Â |
Thoracotomy | 837 (33.06) | 236 (32.46) | 601 (33.30) | Â |
Unknown | 104 (4.11) | 34 (4.68) | 70 (3.88) | Â |
Tumor differentiation, n (%) | Â | Â | Â | 0.045 |
Moderate-Well | 288 (11.37) | 69 (9.49) | 219 (12.13) | Â |
Poor-undifferentiated | 126 (4.98) | 29 (3.99) | 97 (5.37) | Â |
Other | 2118 (83.65) | 629 (86.52) | 1489 (82.49) | Â |
T stage, n (%) | Â | Â | Â | 0.80 |
T1 | 1089 (43.01) | 305 (41.95) | 784 (43.43) | Â |
T2 | 962 (37.99) | 275 (37.83) | 687 (38.06) | Â |
T3 | 293 (11.57) | 93 (12.79) | 200 (11.08) | Â |
T4 | 184 (7.27) | 53 (7.29) | 131 (7.26) | Â |
Unknown | 4 (0.16) | 1 (0.14) | 3 (0.17) | Â |
N stage, n (%) | Â | Â | Â | 0.43 |
N0 | 1546 (61.06) | 453 (62.31) | 1093 (60.55) | Â |
N1 | 233 (9.20) | 68 (9.35) | 165 (9.14) | Â |
N2-N3 | 350 (13.82) | 104 (14.31) | 246 (13.63) | Â |
Unknown | 403 (15.92) | 102 (14.03) | 301 (16.68) | Â |
Histologic Stage, n (%) | Â | Â | Â | 0.15 |
I | 1216 (54.63) | 348 (53.95) | 868 (54.90) | Â |
II | 410 (18.42) | 133 (20.62) | 277 (17.52) | Â |
III | 526 (23.63) | 151 (23.41) | 375 (23.72) | Â |
Unknown | 380 (15.01) | 95 (13.07) | 285 (15.79) | Â |
Histologic type, n (%) | Â | Â | Â | 0.71 |
Adenocarcinoma | 1961 (77.45) | 569 (78.27) | 1392 (77.12) | Â |
Squamous cell carcinoma | 454 (17.93) | 128 (17.61) | 326 (18.06) | Â |
Other | 117 (4.62) | 30 (4.13) | 87 (4.82) | Â |
Pleural invasion, n (%) | Â | Â | Â | 0.66 |
Yes | 425 (16.79) | 121 (16.64) | 304 (16.84) | Â |
No | 2064 (81.52) | 591 (81.29) | 1473 (81.61) | Â |
Unknown | 43 (1.70) | 15 (2.06) | 28 (1.55) | Â |
Adjuvant chemotherapy, n (%) | Â | Â | Â | 0.76 |
Yes | 1216 (48.03) | 357 (49.11) | 859 (47.59) | Â |
No | 1075 (42.46) | 304 (41.82) | 771 (42.71) | Â |
Unknown | 241 (9.52) | 66 (9.08) | 175 (9.70) | Â |